Impact of Anti-PLA2R Antibodies on Thrombosis in Membranous Nephropathy
Author Information
Author(s): Kitlinski Michael, Heleniak Zbigniew, Dębska-Ślizień Alicja
Primary Institution: Medical University of Gdansk
Hypothesis
Do anti-phospholipase A2 receptor antibodies exacerbate hypercoagulability in membranous nephropathy?
Conclusion
Cardiometabolic disturbances may play a larger role than hypercoagulability in thromboembolic events in patients with membranous nephropathy and anti-PLA2R antibodies.
Supporting Evidence
- Patients with anti-PLA2R antibodies have been found to have higher cholesterol levels.
- Statin therapy has been shown to reduce the risk of blood clots in patients with membranous nephropathy.
- Existing studies show conflicting evidence regarding the impact of anti-PLA2R antibodies on coagulation.
Takeaway
This study suggests that having certain antibodies might not just make blood clot more easily; it could also be that other health issues, like cholesterol levels, are more important in causing blood clots.
Limitations
The commentary highlights that existing studies have conflicting results regarding the relationship between anti-PLA2R antibodies and coagulation impairment.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website